FindTrial
Sign In

TUB-030

DRUG2 trials

Sponsors

Tubulis GmbH

Conditions

Advanced Solid TumorsCRCHNSCCNSCLCPatients with advanced/metastatic tumors with head and neck squamous cell carcinomas (HNSCC)SCLCTNBC - Triple-Negative Breast Cancernon-small-cell lung cancer (NSCLC)

Phase 1

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RecruitingNCT06657222
Tubulis GmbHAdvanced Solid Tumors, CRC, HNSCC +3
Start: 2024-12-13End: 2028-12-01Target: 250Updated: 2026-09-11
A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patients with Advanced Solid Tumors (5-STAR 1-01)
Not yet recruitingCTIS2025-522517-35-00
Tubulis GmbHnon-small-cell lung cancer (NSCLC), Patients with advanced/metastatic tumors with head and neck squamous cell carcinomas (HNSCC)
Target: 90Updated: 2025-12-03

Related Papers

TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.
Journal of Clinical Oncology2025-05-281 citations